Crispr Therapeutics [CRSP] vs Bio-Techne [TECH] Detailed Stock Comparison

Crispr Therapeutics AG

NASDAQ
Loading...

Bio-Techne Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Crispr Therapeutics AG wins in 4 metrics, Bio-Techne Corporation wins in 14 metrics, with 0 ties. Bio-Techne Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Crispr Therapeutics AG Bio-Techne Corporation Better
P/E Ratio (TTM) -8.52 117.16 Bio-Techne Corporation
Price-to-Book Ratio 2.77 4.55 Crispr Therapeutics AG
Debt-to-Equity Ratio 10.76 20.07 Crispr Therapeutics AG
PEG Ratio -0.04 -0.82 Crispr Therapeutics AG
EV/EBITDA -6.49 28.87 Bio-Techne Corporation
Profit Margin (TTM) 0.00% 6.41% Bio-Techne Corporation
Operating Margin (TTM) -17,912.50% 14.51% Bio-Techne Corporation
EBITDA Margin (TTM) N/A 14.51% N/A
Return on Equity -30.18% 3.80% Bio-Techne Corporation
Return on Assets (TTM) -15.76% 6.09% Bio-Techne Corporation
Free Cash Flow (TTM) $-370.93M $256.55M Bio-Techne Corporation
Dividend Yield N/A 0.62% N/A
1-Year Return 54.81% 6.78% Crispr Therapeutics AG
Price-to-Sales Ratio (TTM) 1,518.81 7.35 Bio-Techne Corporation
Enterprise Value $3.56B $9.19B Bio-Techne Corporation
EV/Revenue Ratio 1,014.80 7.56 Bio-Techne Corporation
Gross Profit Margin (TTM) N/A 62.72% N/A
Revenue per Share (TTM) $0 $8 Bio-Techne Corporation
Earnings per Share (Diluted) $-6.47 $0.49 Bio-Techne Corporation
Beta (Stock Volatility) 1.79 1.47 Bio-Techne Corporation
Short % of Float 26.43% 5.09% Bio-Techne Corporation

Crispr Therapeutics AG vs Bio-Techne Corporation Stock Performance Analysis

Loading Price Chart...

CRSP
TECH

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Crispr Therapeutics AG0.15%-2.67%-2.76%-10.27%-6.95%-3.11%
Bio-Techne Corporation2.17%5.74%-7.11%-10.77%-20.32%-14.75%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Crispr Therapeutics AG54.81%-13.57%-50.41%306.51%306.51%306.51%
Bio-Techne Corporation6.78%-37.73%-51.28%86.91%161.27%281.12%

Performance & Financial Health Analysis: Crispr Therapeutics AG vs Bio-Techne Corporation

MetricCRSPTECH
Market Information
Market Cap i$5.30B$9.07B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,664,9332,151,790
90 Day Avg. Volume i2,131,1412,370,067
Last Close$52.10$50.85
52 Week Range$36.08 - $78.48$43.20 - $72.16
% from 52W High-33.61%-29.53%
All-Time High$220.20 (Jan 11, 2021)$135.96 (Sep 20, 2021)
% from All-Time High-76.34%-62.60%
Growth Metrics
Quarterly Revenue Growth-0.98%-0.01%
Quarterly Earnings Growth-1.00%0.14%
Financial Health
Profit Margin (TTM) i0.00%0.06%
Operating Margin (TTM) i-179.13%0.15%
Return on Equity (TTM) i-0.30%0.04%
Debt to Equity (MRQ) i10.7620.07
Cash & Liquidity
Book Value per Share (MRQ)$20.04$12.62
Cash per Share (MRQ)$20.59$0.93
Operating Cash Flow (TTM) i$-345,014,016$251.25M
Levered Free Cash Flow (TTM) i$-205,623,744$274.30M
Dividends
Last 12-Month Dividend Yield iN/A0.62%
Last 12-Month Dividend iN/A$0.40

Valuation & Enterprise Metrics Analysis: Crispr Therapeutics AG vs Bio-Techne Corporation

MetricCRSP (Apr 24, 2026)TECH (Nov 10, 2025)
Price Ratios
P/E Ratio (TTM) i-8.52117.16
Forward P/E i-13.2626.21
PEG Ratio i-0.04-0.82
Price to Sales (TTM) i1,518.817.35
Price to Book (MRQ) i2.774.55
Market Capitalization
Market Capitalization i$5.30B$9.07B
Enterprise Value i$3.56B$9.19B
Enterprise Value Metrics
Enterprise to Revenue i1,014.807.56
Enterprise to EBITDA i-6.4928.87
Risk & Other Metrics
Beta i1.791.47
Book Value per Share (MRQ) i$20.04$12.62

Financial Statements Comparison: Crispr Therapeutics AG vs Bio-Techne Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCRSP (2025)TECH (2025)
Revenue/Sales i01.22B
Cost of Goods Sold i213.48M429.36M
COGS % of Revenue i-35.2%
Gross Profit i-213.48M790.27M
Gross Margin i-64.8%
Research & Development i381.06M99.50M
Operating Income (EBIT) i-664.57M242.80M
Operating Margin i-19.9%
EBITDA i-645.09M357.57M
EBITDA Margin i-29.3%
Pre-Tax Income i-577.97M98.46M
Pre-Tax Income % of Revenue i-8.1%
Income Tax i3.63M25.06M
Income Tax % of Revenue i-2.1%
Net Income (Profit) i-581.60M73.40M
Profit Margin i-6.0%

Balance Sheet & Liquidity Metrics

MetricCRSP (2025)TECH (2025)
Cash & Equivalents i347.56M162.19M
Total Current Assets i1.99B608.30M
Total Current Assets % of Revenue i-49.9%
Total Current Liabilities i149.12M175.85M
Total Current Liabilities % of Revenue i-14.4%
Long-Term Debt i188.17M429.96M
Long-Term Debt % of Revenue i-35.3%
Total Shareholders Equity i1.92B1.92B
Retained Earnings i-1.95B1.07B
Retained Earnings % of Revenue i-87.4%
Property, Plant & Equipment i175.30M73.40M

Cash Flow Statement Comparison

MetricCRSP (2025)TECH (2025)
Operating Cash Flow i-393.25M185.64M
Operating Cash Flow % of Revenue i-15.2%
Capital Expenditures i-914,000-31.01M
Free Cash Flow i-370.93M256.55M
FCF Margin i-21.0%
Debt Repayment iN/A-77.00M
Common Stock Repurchase iN/A-275.73M

Short Interest & Institutional Ownership Analysis

MetricCRSPTECH
Shares Short i22.62M6.94M
Short Ratio i10.012.59
Short % of Float i26.43%5.09%
Shares Outstanding i95.89M154.97M
Float Shares i95.55M153.94M
% Held by Insiders i4.88%0.28%
% Held by Institutions i73.33%102.89%
% Held by Public i21.79%-3.17%

Dividend Analysis & Yield Comparison: Crispr Therapeutics AG vs Bio-Techne Corporation

MetricCRSPTECH
Last 12-Month Dividend iN/A$0.40
Last 12-Month Dividend Yield iN/A0.62%
3-Year Avg Annual Dividend iN/A$0.32
3-Year Avg Dividend Yield iN/A0.12%
3-Year Total Dividends iN/A$0.96
Ex-Dividend DateN/AFeb 13, 2026